CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy

Diana M. Escolar, Gunnar Buyse, Erik Henricson, Robert Leshner, Julaine Florence, Jill Mayhew, Carolina Tesi-Rocha, Ksenija Gorni, Livia Pasquali, Kantilal M. Patel, Robert McCarter, Jennifer Huang, Thomas Mayhew, Tulio Bertorini, Jose Carlo, Anne M. Connolly, Paula R. Clemens, Nathalie Goemans, Susan T. Iannaccone, Masanori IgarashiYoram Nevo, Alan Pestronk, S. H. Subramony, V. V. Vedanarayanan, Henry Wessel

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, doubleblind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.

Original languageEnglish (US)
Pages (from-to)151-155
Number of pages5
JournalAnnals of Neurology
Volume58
Issue number1
DOIs
StatePublished - Jul 2005

Fingerprint

Duchenne Muscular Dystrophy
Creatine
Glutamine
Randomized Controlled Trials
Muscle Strength
Muscles
Respiratory Function Tests
Controlled Clinical Trials
Placebos
Outcome Assessment (Health Care)
Safety
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Escolar, D. M., Buyse, G., Henricson, E., Leshner, R., Florence, J., Mayhew, J., ... Wessel, H. (2005). CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Annals of Neurology, 58(1), 151-155. https://doi.org/10.1002/ana.20523

CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. / Escolar, Diana M.; Buyse, Gunnar; Henricson, Erik; Leshner, Robert; Florence, Julaine; Mayhew, Jill; Tesi-Rocha, Carolina; Gorni, Ksenija; Pasquali, Livia; Patel, Kantilal M.; McCarter, Robert; Huang, Jennifer; Mayhew, Thomas; Bertorini, Tulio; Carlo, Jose; Connolly, Anne M.; Clemens, Paula R.; Goemans, Nathalie; Iannaccone, Susan T.; Igarashi, Masanori; Nevo, Yoram; Pestronk, Alan; Subramony, S. H.; Vedanarayanan, V. V.; Wessel, Henry.

In: Annals of Neurology, Vol. 58, No. 1, 07.2005, p. 151-155.

Research output: Contribution to journalArticle

Escolar, DM, Buyse, G, Henricson, E, Leshner, R, Florence, J, Mayhew, J, Tesi-Rocha, C, Gorni, K, Pasquali, L, Patel, KM, McCarter, R, Huang, J, Mayhew, T, Bertorini, T, Carlo, J, Connolly, AM, Clemens, PR, Goemans, N, Iannaccone, ST, Igarashi, M, Nevo, Y, Pestronk, A, Subramony, SH, Vedanarayanan, VV & Wessel, H 2005, 'CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy', Annals of Neurology, vol. 58, no. 1, pp. 151-155. https://doi.org/10.1002/ana.20523
Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Annals of Neurology. 2005 Jul;58(1):151-155. https://doi.org/10.1002/ana.20523
Escolar, Diana M. ; Buyse, Gunnar ; Henricson, Erik ; Leshner, Robert ; Florence, Julaine ; Mayhew, Jill ; Tesi-Rocha, Carolina ; Gorni, Ksenija ; Pasquali, Livia ; Patel, Kantilal M. ; McCarter, Robert ; Huang, Jennifer ; Mayhew, Thomas ; Bertorini, Tulio ; Carlo, Jose ; Connolly, Anne M. ; Clemens, Paula R. ; Goemans, Nathalie ; Iannaccone, Susan T. ; Igarashi, Masanori ; Nevo, Yoram ; Pestronk, Alan ; Subramony, S. H. ; Vedanarayanan, V. V. ; Wessel, Henry. / CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. In: Annals of Neurology. 2005 ; Vol. 58, No. 1. pp. 151-155.
@article{dc0788ee22a64ac6bdb27e938d188656,
title = "CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy",
abstract = "We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, doubleblind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.",
author = "Escolar, {Diana M.} and Gunnar Buyse and Erik Henricson and Robert Leshner and Julaine Florence and Jill Mayhew and Carolina Tesi-Rocha and Ksenija Gorni and Livia Pasquali and Patel, {Kantilal M.} and Robert McCarter and Jennifer Huang and Thomas Mayhew and Tulio Bertorini and Jose Carlo and Connolly, {Anne M.} and Clemens, {Paula R.} and Nathalie Goemans and Iannaccone, {Susan T.} and Masanori Igarashi and Yoram Nevo and Alan Pestronk and Subramony, {S. H.} and Vedanarayanan, {V. V.} and Henry Wessel",
year = "2005",
month = "7",
doi = "10.1002/ana.20523",
language = "English (US)",
volume = "58",
pages = "151--155",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy

AU - Escolar, Diana M.

AU - Buyse, Gunnar

AU - Henricson, Erik

AU - Leshner, Robert

AU - Florence, Julaine

AU - Mayhew, Jill

AU - Tesi-Rocha, Carolina

AU - Gorni, Ksenija

AU - Pasquali, Livia

AU - Patel, Kantilal M.

AU - McCarter, Robert

AU - Huang, Jennifer

AU - Mayhew, Thomas

AU - Bertorini, Tulio

AU - Carlo, Jose

AU - Connolly, Anne M.

AU - Clemens, Paula R.

AU - Goemans, Nathalie

AU - Iannaccone, Susan T.

AU - Igarashi, Masanori

AU - Nevo, Yoram

AU - Pestronk, Alan

AU - Subramony, S. H.

AU - Vedanarayanan, V. V.

AU - Wessel, Henry

PY - 2005/7

Y1 - 2005/7

N2 - We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, doubleblind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.

AB - We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, doubleblind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=21844474016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21844474016&partnerID=8YFLogxK

U2 - 10.1002/ana.20523

DO - 10.1002/ana.20523

M3 - Article

C2 - 15984021

AN - SCOPUS:21844474016

VL - 58

SP - 151

EP - 155

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -